New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
07:12 EDTSGENSeattle Genetics 2014 Adcetris guidance good, says RBC Capital
RBC Capital noted that Seattle Genetics' guidance for 2014 Adcetris sales was in-line with RBC Capital's estimate but below the consensus outlook. RBC Capital thinks the consensus outlook was flawed as it failed to take into account the lack of major catalysts for the drug until possibly late 2014. RBC Capital keeps an Outperform rating on Seattle Genetics.
News For SGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
11:20 EDTSGENSeattle Genetics likely to gain approval in post-transplant HL, says Piper
Subscribe for More Information
09:01 EDTSGENSeattle Genetics says FDA accepts sBLA for Adcetris
Subscribe for More Information
April 10, 2015
07:21 EDTSGENExpert upbeat on Seattle Genetics Adcetris, says RBC Capital
After meeting with an expert, RBC Capital reports that he believes that off-label use of Seattle Genetics' Adcetris is increasing across a variety of indications. He believes that Adcetris is approvable and has a better chance of becoming a front-line treatment than competing drugs. The firm keeps a $50 price target and Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use